HCW Biologics Inc. (HCWB) News
Follow HCW Biologics Inc. (HCWB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
HCW Biologics Secures $10.2 Million in Notes Financing
HCW Biologics entered into a purchase agreement for $10.2 million in secured notes, closing November 4, 2026. The financing comprises a $3.2 million A-1 Note and a $7.0 million B Note.
EQUITY | Nov 05, 2026, 02:13 PM UTC
L
HCW Biologics Secures Up to $10.0 Million Through Debt Financing
HCW Biologics secured up to $10.0 million in cash through debt financing.
EQUITY | Nov 05, 2026, 01:45 PM UTC
L
HCW Biologics Raises $1.5 Million in Private Placement of Pre-Funded Warrants; Common Warrants Pending Vote
HCW Biologics entered into a Securities Purchase Agreement with an existing institutional investor to raise approximately $1.5 million through the sale of 903,614 units at $1.6599 per unit. Each unit includes a pre-funde
NEWS | Sep 24, 2026, 01:06 PM UTC
L
HCW Biologics Inc. (HCWB) Prices $1.5M Private Placement
HCW Biologics priced a $1.5M private placement of 903,614 units to an existing stockholder, each with a pre-funded warrant and a right to receive a common warrant subject to stockholder approval.Material DetailsContext b
NEWS | Sep 24, 2026, 12:33 PM UTC
L
HCW Biologics Announces Pricing of $1.5M Private Placement
HCW Biologics Announces Pricing of $1.5M Private Placement
NEWS | Sep 24, 2026, 12:29 PM UTC
L
HCWB - HCW Biologics Announces Pricing of $1.5 Million Private Placement
HCWB - HCW Biologics Announces Pricing of $1.5 Million Private Placement
NEWS | Sep 24, 2026, 12:25 PM UTC
L
HCW Biologics removes equity-plan proposal, reschedules special meeting
The company said it will remove Proposal No. 2, an amended performance-based equity plan, from its preliminary proxy. It also said it will reschedule the special meeting.
EQUITY | Sep 10, 2026, 10:03 AM UTC
L
HCW Biologics enters exclusive distribution deal for HCW11-006
HCW Biologics entered an exclusive distribution agreement with Akron Biotech to commercialize HCW11-006 as a reagent used to support production of highly functional human CAR-T cells.
EQUITY | Sep 08, 2026, 12:57 PM UTC
L
HCW Biologics strengthens U.S. patent estate for HCW9302 alopecia areata
HCW Biologics says it has strengthened its U.S. patent estate for HCW9302, its lead clinical-stage immunotherapeutic for alopecia areata.
EQUITY | Sep 02, 2026, 01:00 PM UTC
L
HCW Biologics highlights TGF-β trap and IL-15 fusion immunotherapy approach
HCW Biologics says its TGF-β trap and IL-15 fusion platform is a novel moiety intended to enhance immunotherapeutic activity against diseased cells.
EQUITY | Aug 25, 2026, 01:00 PM UTC
L
HCWB files S-1 for up to 1,237,364 shares
HCWB files Form S-1 covering up to 1,237,364 shares of common stock.
REGULATION | Aug 20, 2026, 07:03 PM UTC
M
HCW Biologics reports Q2 2026 business and clinical highlights
HCW Biologics (HCWB) reports second quarter 2026 business and clinical development highlights and financial results, according to TradeXchange Newsdesk.
EQUITY | Aug 14, 2026, 07:15 PM UTC
L
HCWB - HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering
HCWB - HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering
EQUITY | Jul 29, 2026, 01:06 PM UTC
L
HCW Biologics Regains Nasdaq Compliance After Announcing 1-For-6 Reverse Stock Split, Effective June 30
HCW Biologics Inc. (the "Company" or "HCW Biologics") (Nasdaq: HCWB ), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by ch
EQUITY | Jun 30, 2026, 12:26 PM UTC
L
HCWB Announces Reverse Split
HCW Biologics announces a 1-for-6 reverse stock split effective June 30, 2026
EQUITY | Jun 26, 2026, 12:55 PM UTC